NCT00391014View on ClinicalTrials.gov

Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Acute Myeloid LeukemiaAllogeneic Haematopoietic Progenitor Cell Transplant
Interventions
DRUG

liposomal Amphotericine B

"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."

Trial Locations (4)

Unknown

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitario de la Princesa, Madrid

Hospital Universitario la Fe, Valencia

Hospital Universitario de Salamanca, Salamanca

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00391014 - Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis | Biotech Hunter | Biotech Hunter